Compare KELYB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | ZVRA |
|---|---|---|
| Founded | 1946 | 2006 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.9M | 766.1M |
| IPO Year | N/A | 2015 |
| Metric | KELYB | ZVRA |
|---|---|---|
| Price | $23.16 | $12.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 1.2K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | $0.72 | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $20.23 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $8.38 | $7.16 |
| 52 Week High | $125.00 | $15.04 |
| Indicator | KELYB | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 39.59 |
| Support Level | $11.84 | $8.26 |
| Resistance Level | $125.00 | $12.05 |
| Average True Range (ATR) | 1.63 | 0.66 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 72.49 | 1.57 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.